^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).
Published date:
05/13/2020
Excerpt:
With TALA, PFS was significantly shorter in pts with TP53 mutations than without [HR (95% CI) 1.693 (1.186-2.418), P = 0.0033]. A similar, non-significant, trend was evident with PCT [HR (95% CI) 1.439 (0.859-2.411), P = 0.1614]….TP53 mutations were associated with shorter PFS, likely reflecting the worse outcomes observed in gBRCA1m patients.
DOI:
10.1200/JCO.2020.38.15_suppl.1018
Trial ID:
Test:
